HCG vs Letrozole
FDA Approved vs FDA Approved
monitor Researched · 90% HCG stimulates intratesticular aromatase activity directly, producing estradiol independently of peripheral aromatization. This can partially counteract letrozole's systemic aromatase inhibition. When combining HCG with letrozole, be aware that estradiol levels may be less suppressed than expected, and dose adjustments may be needed. Monitor bloodwork.
Molecular Data
HCG Letrozole
Weight 36,700 Da 285.30 Da
Half-life 24-36 hours ~2 days (48 hours)
Chain 237 amino acids (alpha: 92, beta: 145) —
Type Heterodimeric glycoprotein Nonsteroidal aromatase inhibitor (triazole derivative)
Key Benefits
HCG
01 Maintains testicular function during TRT
02 Preserves fertility and prevents testicular atrophy
03 Stimulates endogenous testosterone production
04 Induces ovulation in women
05 FDA-approved for multiple indications
06 Well-established safety profile
Letrozole
01 Most potent aromatase inhibitor available, achieving ~98% estradiol suppression at medical doses
02 Effective rescue compound for acute gynecomastia flare-ups unresponsive to other AIs
03 Capable of managing estrogen on very high aromatizing cycles where anastrozole is insufficient
04 Oral dosing with a 2-day half-life supports every-other-day scheduling
05 Well-characterized pharmacokinetics with extensive clinical data from breast cancer treatment
06 Reversible inhibition allows estrogen recovery after discontinuation
07 FDA-approved with decades of safety and efficacy data
Dosing Protocols
HCG
250-1500 IU (lower for TRT adjunct, higher for fertility) / 2-3 times weekly, or every other day for lower doses
TRT Adjunct (Low) 250-500 IU Every other day
TRT Adjunct (Standard) 500-1000 IU Twice weekly
HCG Monotherapy 1500-2000 IU 2-3x weekly
Fertility (with FSH) 1500-2000 IU 2-3x weekly
Cryptorchidism (Pediatric) 1000-5000 IU 2-3x weekly for 3-4 weeks
Ovulation Trigger (Female) 5000-10,000 IU Single dose
PCT Protocol 1000-1500 IU Every other day for 2-3 weeks
Letrozole
0.25-0.5mg EOD (on-cycle); 2.5mg/day (medical) / Every other day (cycle support); daily (breast cancer / fertility)
Side Effects
HCG
Gynecomastia (breast tenderness/swelling) due to increased estrogen
Headaches, irritability, and mood swings (especially initially)
Fluid retention and edema
Potential antibody formation with long-term use
Letrozole
Severe joint pain, stiffness, and dryness (the hallmark side effect of aggressive estrogen suppression)
Fatigue and profound lethargy
Mood disturbance (depression, emotional flatness, irritability)
Decreased libido and sexual dysfunction
Hot flashes or flushing
Headache
Muscle aches and generalized pain
Contraindications
Hormone-sensitive cancers (prostate, breast)
Pregnancy (except as prescribed)
Precocious puberty risk in children
Known hypersensitivity to letrozole or any excipients
Premenopausal women (unless under specialist care for fertility treatment)
Pregnancy or breastfeeding (teratogenic risk -- letrozole is Category X)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
History of estrogen-crash-related adverse events with prior AI use
Research Evidence
HCG Letrozole
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2024 —
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.